Out-licensing

We are eager to out-license our biotechnologies to mRNA players for the development of mRNA vaccines and therapies, as well as cell therapies (iPS, CAR-T cells and CAR-NK cells) and gene editing.

Last news

Vaccines Glimpses (1)-1

Jérôme Lemoine was a plenary speaker at the 4th International…

posted January 30, 2026

He presented Messenger Biopharma’s capless ...Read More

Recent Search Keywords